Ustekinumab as induction and maintenance therapy for Crohn's disease

New England Journal of Medicine

Volumn 375, Issue 20, 2016, Pages 1946-1960

  Feagan, Brian G ^a   Sandborn, William J ^d   Gasink, Christopher ^f   Jacobstein, Douglas ^f   Lang, Yinghua ^f   Friedman, Joshua R ^f   Blank, Marion A ^g   Johanns, Jewel ^f   Gao, Long Long ^f   Miao, Ye ^f   Adedokun, Omoniyi J ^f   Sands, Bruce E ^h   Hanauer, Stephen B ^j   Vermeire, Severine ^k   Targan, Stephan ^e   Ghosh, Subrata ^b   De Villiers, Willem J ^l   Colombel, Jean Frederic ^h   Tulassay, Zsolt ^m   Seidler, Ursula ⁿ   Salzberg, Bruce A ^o   Desreumaux, Pierre ^p   Lee, Scott D ^q   Loftus, Edward V ^r   Dieleman, Levinus A ^c   Katz, Seymour ⁱ   Rutgeerts, Paul ^k   Bampton, P ^s   Chung, A ^s   Connor, S ^s   Debinski, H ^s   Leong, R ^s   Macrae, F ^s   Pavli, P ^s   Sorrentino, D ^s   van den Bogaerde, J ^s   Vogel, W ^s   Vogelsang, H ^s   Louis, E ^s   Mana, F ^s   Zaltman, C ^s   Aumais, G ^s   Bernstein, C ^s   Bressler, B ^s   Dhalla, S ^s   Marshall, J ^s   Panaccione, R ^s   Ropeleski, M ^s   Stehlik, J ^s   Volfova, M ^s   Brynskov, J ^s   Glerup, H ^s   Abitbol Selinger, V ^s   Allez, M ^s   Beaugerie, L ^s   Bourreille, A ^s   Cadiot, G ^s   Dupas, J ^s   Grimaud, J ^s   Laharie, D ^s   Lerebours, E ^s   Moreau, J ^s   Baumgart, D ^s   Brand, S ^s   Ebert, M ^s   Ehehalt, R ^s   Hasselblatt, P ^s   Howaldt, S ^s   Klaus, J ^s   Krummenerl, P ^s   Kucharzik, T ^s   Lugering A ^s   Mudter, J ^s   Preiss, J ^s   Schreiber, S ^s   Stallmach, A ^s   Stein, J ^s   Strauch, U ^s   Salamon, A ^s   Patchett, S ^s   Lahat Zok, A ^s   Rachmilewitz, D ^s   Annese, V ^s   Bossa, F ^s   Guidi, L ^s   Kohn, A ^s   Rocca, R ^s   Ando, A ^s   Ashida, T ^s   Hanai, H ^s   Ishida, T ^s   Ito, H ^s   Matsumoto, T ^s   Motoya, S ^s   Nakamura, S ^s   Sameshima, Y ^s   Suzuki, Y ^s   Watanabe, K ^s   Yamagami, H ^s   Yamamoto, T ^s   Yao, K ^s   Kim, H ^s   Kim, Y ^s   D'Haens, G ^s   Pierik, M ^s   van Bodegraven, A ^s   van der Woude, C J ^s   Gearry, R ^s   Ciecko Michalska, I ^s   Malecka Panas, E ^s   Jojic, N ^s   Aboo, N ^s   Wright, J ^s   Arranz, M ^s   Viso, L ^s   Ahmad, T ^s   Bloom, S ^s   Campbell, S ^s   Creed, T ^s   Cummings, F ^s   Hawthorne, B ^s   Iqbal, T ^s   Ireland, A ^s   Parkes, M ^s   Pollok, R ^s   Shaw, I ^s   Shonde, A ^s   Smith, M ^s   Steel, A ^s   Subramanian, S ^s   Travis, S ^s   Tremelling, M ^s   Aberra, F ^s   Abraham, B ^s   Barish, C ^s   Behm, B ^s   Birbara, C ^s   Bochner, R ^s   Bologna, S ^s   Brant, S ^s   Charles, R ^s   Cohen, N ^s   de Villers, W ^s   Dryden, G ^s   DuVall, A ^s   Flasar, M ^s   Fleisher, M ^s   Florez, D ^s   Fogel, R ^s   Gagneja, H ^s   Gross, C ^s   Hamilton, J ^s   Hanson, J ^s   Hardi, R ^s   Higgins, P ^s   Isaacs, K ^s   Katz, J ^s   Kaur, N ^s   Khan, N ^s   Leman, B ^s   Levenson, S ^s   Lichtiger, S ^s   Malik, P ^s   McNair, A ^s   Melmed, G ^s   Miner, P ^s   Nichols, M ^s   Noar, M ^s   Oikonomou, I ^s   Oubre, B ^s   Peterson, K ^s   Pruitt, R ^s   Quirk, D ^s   Safdi, A ^s   Safdi, M ^s   Saubermann, L ^s   Scherl, E ^s   Schwartz, D ^s   Schwarz, R ^s   Sedghi, S ^s   Selby, L ^s   Shafran, I ^s   Siegel, C ^s   Sninsky, C ^s   Stern, M ^s   Stockwell, D ^s   Stone, C ^s   Swaminath, A ^s   Swoger, J ^s   Taormina, M ^s   Williams, E ^s   Winstead, N ^s   Wolf, D ^s   Wolosin, J ^s   Yacyshyn, B ^s   Yajnik, V ^s   Yen, E ^s   Hetzel, D ^s   Muls, V ^s   Bafutto, M ^s   Francesconi, C ^s   Sipahi, A ^s   Steinwurz, F ^s   Churchev, J ^s   Kotzev, I ^s   Marinova, I ^s   Penchev, P ^s   Spassova, Z ^s   Stoinov, S ^s   Takov, D ^s   Vassileva, G ^s   Fowler, S ^s   Greenberg, G ^s   Jones, J ^s   Saibil, F ^s   Salh, B ^s   Banic M ^s   Duvnjak, M ^s   Stimac, D ^s   Goujon, G ^s   Pelletier, A ^s   Peyrin Biroulet, L ^s   Aldinger, V ^s   Bokemeyer, B ^s   Buning C ^s   Konturek, J ^s   Krummenerl, T ^s   Ochsenkuehn, T ^s   Altorjay, I ^s   Kis, J ^s   Pecsi, G ^s   Szekely A ^s   Varga, M ^s   Vincze, A ^s   Wacha, J ^s   Oddsson, E ^s   Orvar, K ^s   Avni Biron, I ^s   Fishman, S ^s   Fraser, G ^s   Konikoff, F ^s   Melzer, E ^s   Oren, R ^s   Shirin, H ^s,s   Danese, S ^s   Marino, M ^s   Sturniolo, G C ^s   Horiki, N ^s   Iijima, H ^s   Iwabuchi, M ^s   Kanai, T ^s   Kunisaki, R ^s   Maemoto, A ^s   Matsuoka, K ^s   Osada, T ^s   Sugimoto, K ^s   Tanaka, S ^s   Cheon, J H ^s   Han, D S ^s   Jang, B I ^s   Kim, J S ^s   Park, S J ^s   Yang, S K ^s   Arnold, M ^s   Claydon, A ^s   Haines, M ^s   Hill, J ^s   Rowbotham, D ^s   Schultz, M ^s   Wallace, I ^s   Bochenek, A ^s   Niezgoda, K ^s   Szura, M ^s   Arutyunov, G ^s   Baranovsky, A ^s   Khalif, I ^s   Osipenko, M ^s   Milinic, N ^s   Bloch, H ^s   Kruger, F C ^s   Prins, M ^s   Watermeyer, G ^s   Ziady, C ^s   Calvo, XC ^s   Dominguez Munoz J E ^s   Gisbert, J P ^s   Arsenescu, R ^s   Beaulieu, D ^s   Bedford, R ^s   Behrend, C ^s   Cleavinger, P ^s   Cohen, J ^s   Ertan, A ^s   Freilich, B ^s   Friedenberg, K ^s   Glover, S ^s   Gordon, G ^s   Gunaratnam, N ^s   Gupta, N ^s   Holbrook, R ^s   Jones, M ^s   Kaufman, B ^s   Khurana, S ^s   Legnani, P ^s   Mutlu, E ^s   Phillips, R ^s   Rai, R ^s   Reichelderfer, M ^s   Ritter, T ^s   Safdi, M A ^s   Schulman, M ^s   Smith, J ^s   Suiter, D ^s   Taylor, D ^s   Vasudeva, R ^s   Winstead, T ^s   Zwick, A ^s   Savoye, G ^s   Atreya, R ^s   Ochsenkuhn, T ^s   Ott, C ^s   Goldin, E ^s   Motohiro, E ^s   Takanori, K ^s   James, B ^s   Cummings, J ^s   Tariq, A ^s   Willert, R ^s   Allan, M ^s   Bulat, R ^s   deVilliers, W ^s   Eaker, E ^s   Hou, J ^s   Mendu, S ^s   Nicols, M ^s   Proctor, D ^s   Thosani, N ^s   Zhang, C ^s   more..

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^g Janssen Scientific Affairs LLC   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^l STELLENBOSCH UNIVERSITY   (South Africa)

^m SEMMELWEIS UNIVERSITY   (Hungary)

ⁿ HANNOVER MEDICAL SCHOOL   (Germany)

^o Atlanta Gastroenterology Specialists PC   (United States)

^p LILLE UNIVERSITY HOSPITAL   (France)

^q UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^r MAYO CLINIC   (United States)

^s NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; USTEKINUMAB;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; RHINOPHARYNGITIS; TREATMENT RESPONSE; IMMUNOLOGY; INDUCTION CHEMOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; CROHN DISEASE; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; INFUSIONS, INTRAVENOUS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; REMISSION INDUCTION; USTEKINUMAB;

EID: 84995563335     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1602773     Document Type: Article

References (19)

1. Biancone L, Tosti C, Fina D, et al. Review article: maintenance treatment of Crohn's disease. Aliment Pharmacol Ther 2003; 17: Suppl 2: 31-7.
2. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367: 1519-28.
3. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
4. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-36.
5. Rutgeerts PJ. The limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther 2001; 15: 1515-25.
6. Konidari A, Matary WE. Use of thiopurines in inflammatory bowel disease: safety issues. World J Gastrointest Pharmacol Ther 2014; 5: 63-76.
7. Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 2004; 53: 780-2.
8. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab-and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107: 1051-63.
9. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147(3): 618-627.e3.
10. Stelara (ustekinumab) for subcutaneous use. Horsham, PA: Janssen Biotech, March 2014 (package insert).
11. Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168: 844-54.
12. Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol 2015; 14: 706-14.
13. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's Disease Activity Index. Gastroenterology 1976; 70: 439-44.
14. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122: 512-30.
15. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-tosevere Crohn's disease. Gastroenterology 2008; 135: 1130-41.
16. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
17. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33.
18. Gottlieb AB, Kalb RE, Langley RG, et al. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol 2014; 13: 1441-8.
19. Kavanaugh A, Puig L, Gottlieb AB, et al. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res (Hoboken) 2015; 67: 1739-49.